Metabolic Profiling and Quantification of Neurotransmitters in Mouse Brain by Gas Chromatography‐Mass Spectrometry. Issue 3 (1st September 2016)

• Record Type: Journal Article
• Authors: Jäger, Christian; Hiller, Karsten; Buttini, Manuel
• Editors: Auwerx, Johan; Ackerman, Susan L.; Brown, Stephen D.; Justice, Monica J.; Nadeau, Joseph
• Is Part Of: Current protocols in mouse biology. Volume 6:Issue 3(2016)
• Page Start: 333
• Page End: 342
• Publication Date: 2016-09-01
• Subjects: metabolomics -- mouse brain -- GC‐MS -- neurotransmitters -- extraction; Mice -- Genetics -- Laboratory manuals; Mice; Animals, Laboratory; Research; Mice -- Genetics; Periodicals; Laboratory manuals; 616.027333
• DOI: 10.1002/cpmo.15
• Languages: English
• ISSNs: 2161-2617

Abstract

Abstract: Metabolites are key mediators of cellular functions, and have emerged as important modulators in a variety of diseases. Recent developments in translational biomedicine have highlighted the importance of not looking at just one disease marker or disease inducing molecule, but at populations thereof to gain a global understanding of cellular function in health and disease. The goal of metabolomics is the systematic identification and quantification of metabolite populations. One of the most pressing issues of our times is the understanding of normal and diseased nervous tissue functions. To ensure high quality data, proper sample processing is crucial. Here, we present a method for the extraction of metabolites from brain tissue, their subsequent preparation for non‐targeted gas chromatography‐mass spectrometry (GC‐MS) measurement, as well as giving some guidelines for processing of raw data. In addition, we present a sensitive screening method for neurotransmitters based on GC‐MS in selected ion monitoring mode. The precise multi‐analyte detection and quantification of amino acid and monoamine neurotransmitters can be used for further studies such as metabolic modeling. Our protocol can be applied to shed light on nervous tissue function in health, as well as neurodegenerative disease mechanisms and the effect of experimental therapeutics at the metabolic level. © 2016 by John Wiley & Sons, Inc.